Quantum Labs
Español (México)
CJC-1295 + Ipamorelin 5 mg + 5 mgPack de 10 viales6 en stockAhorra 22%
Destacadopeptideintermediate6 en stock

CJC-1295 + Ipamorelin 5 mg + 5 mg

Combinación clásica de GHRH + mimético de grelina

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

Dosis
5mg + 5mg / vial
Forma
Polvo liofilizado
Pack
Pack de 10 viales

Solo para uso en investigación. Este compuesto se vende estrictamente para investigación in vitro y fines de laboratorio, y no está destinado al consumo humano ni a uso terapéutico. Al comprar, usted confirma que es un investigador calificado y acepta nuestro aviso legal completo.

$3,820 MXN
Ahorra 22%
Pack de 10 viales
Antes $4,896 MXN
Se vende en pack de 10 viales

Solo quedan 6 packs

🧪Verificado en laboratorio
✓Analizado por terceros
⚡Envío internacional rápido
🔒Pago con tarjeta seguro
Descripción

Vial de investigación combinado que empareja el análogo de GHRH CJC-1295 con el mimético selectivo de grelina Ipamorelin. La combinación de secretagogos de GH de doble mecanismo más estudiada en la investigación de péptidos.

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

Mecanismo

CJC-1295 respalda la señalización basal del receptor de GHRH, mientras que Ipamorelin impulsa pulsos selectivos del receptor de grelina. La investigación sugiere patrones sinérgicos y naturalistas de liberación de GH en sujetos de estudio.

Informe de laboratorio

Verificado por HPLC frente a una especificación de pureza ≥99 %. Analizado de forma independiente por laboratorios acreditados de terceros.

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

FAQ para investigadores

CJC-1295 + Ipamorelin — preguntas frecuentes

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

Lecturas relacionadas

Guías relacionadas con CJC-1295 + Ipamorelin

Compuestos relacionados

Los investigadores también exploran